GH1 and prostate cancer: In the whole IGHD Itabaianinha cohort, during 25 years of medical care, our team did not diagnose any cases of breast, colon, or prostate cancers (Aguiar‐Oliveira & Salvatori, 2020), suggesting reduced risk of cancer, as shown in Ecuadorian GH‐resistant individuals (Guevara‐Aguirre et al., ,1993, 2011).